Feedback
BCR-ABL1 Mutation Analysis by Next Generation Sequencing
2008420
Ordering Recommendation
Order only for patients with an established diagnosis of a BCR-ABL1 positive leukemia. This test is used to determine if a mutation is present that would interfere with response to TKI therapy in Philadelphia chromosome positive (Ph+) lymphoblastic leukemia or chronic myelogenous leukemia (CML). The test detects all common mutations, including T315I. For initial BCR-ABL1 testing, refer to the reflex test (2005010).
Mnemonic
BCRABL NGS
Methodology
Massively Parallel Sequencing
Performed
Varies
Reported
10-12 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
 
Collect
Lavendar (EDTA) or bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood or 3 mL bone marrow. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum or plasma. Specimens collected in anticoagulants other than EDTA. Frozen Specimens. Clotted or serverely hemolyzed specimens.  
Remarks
 
Stability
Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
Interpretive Data
Refer to report


Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
CPT Code(s)
81170
Components
Component Test Code*Component Chart NameLOINC
2008421BCR-ABL1 Mutation by NGS Source31208-2
2008422BCR-ABL1 Mutation by NGS Result55135-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • ABL Mutation (BCR-ABL1 Kinase Domain Mutation Analysis)
  • ABL1 Mutation Analysis for Imatinib (BCR-ABL1 Kinase Domain Mutation Analysis)
  • BCR-ABL1 Domain Mutation Analysis
  • BCR-ABL1 Mutation (BCR-ABL1 Domain Mutation Analysis)
  • Gleevec Resistance Mutation Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)
  • Imatinib Mesylate Resistance Analysis (BCR-ABL1 Kinase Domain Mutation)
  • Imatinib Resistance Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)
  • TKI Therapy Resistance